Yonhap Infomax NewsSK Biopharmaceuticals Co. delivered a surprise Q2 operating profit, driven by record US sales of its epilepsy drug Xcopri, with revenue and profit far exceeding market forecasts and strong momentum in both core and royalty streams.
#YonhapInfomax #SKBiopharmaceuticals #Xcopri #OperatingProfit #USSales #EpilepsyDrug #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=75569
#YonhapInfomax #SKBiopharmaceuticals #Xcopri #OperatingProfit #USSales #EpilepsyDrug #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=75569
SK Biopharmaceuticals Posts Surprise Q2 Operating Profit Surge—Driven by Xcopri Sales (Comprehensive Report 2)
SK Biopharmaceuticals Co. delivered a surprise Q2 operating profit, driven by record US sales of its epilepsy drug Xcopri, with revenue and profit far exceeding market forecasts and strong momentum in both core and royalty streams.